Clinical Response and Reduction in Medication Use After Deep Brain Stimulation Surgery in a Cohort of Parkinson’s Disease Patients in Colombia
Objective: The objective is to investigate the clinical outcomes and subsequent use of medications in a group of Colombian Patients with DBS Surgery. Background: Parkinson's…A comprehensive at-home and in-hospital work-up of patients with Parkinson’s disease receiving fosflevodopa/fosfcarbidopa continuous subcutaneous infusion
Objective: Continuous infusion of fosflevodopa/foscarbidopa is a promising treatment for patients with Parkinson’s disease (PD) and severe motor fluctuations unresponsive to conventional therapy. Patient selection…The impact of long-term continuous subcutaneous apomorphine infusion on the reduction of remaining medications in levodopa equivalent dosage and on increasing plasma vitamin B12 levels in patients with advanced Parkinson’s disease
Objective: To evaluate the plasma levels of vitamin B and homocysteine among 28 advanced PD patients with motor complications before and after continued used of…Effectiveness of Subthalamic nucleus (STN) Deep Brain Stimulation Surgery (DBS) in patients with Parkinson’s Disease: A Patient and Caregiver reported outcome
Objective: We aim to assess the subjective impression on effectiveness and safety of Subthalamic nucleus Deep Brain Stimulation Surgery (STN-DBS) in patients with Parkinson’s Disease…Levodopa-Entacapone-Carbidopa Intestinal Gel in the treatment of advanced Parkinson’s disease: a two-year experience
Objective: To evaluate the efficacy of Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIG) in the treatment of patients with advanced Parkinson’s Disease (APD). Background: The continuous enteral infusion…Multicenter study of efficacy and safety of subcutaneous foslevodopa/foscarbidopa treatment initiation or switch from LD/CD intestinal gel
Objective: To describe a series of patients under treatment with subcutaneous foslevodopa/foscarbidopa, either as initiation therapy or after switching from intestinal levodopa/carbidopa. Background: Treatment with…Clinical characteristics associated with early discontinuation of Levodopa-Carbidopa Intestinal Gel infusion in patients with advanced Parkinson Disease.
Objective: To determine the clinical characteristics associated with early withdrawal of Levodopa-Carbidopa Intestinal Gel infusion (LCIG) in patients with advanced Parkinson´s Disease (APD) Background: LCIG…Carbidopa does not cause changes in QTc interval even at a supratherapeutic dose
Objective: To assess the cardiac safety of a single supratherapeutic dose of carbidopa in healthy adults. Background: Carbidopa has been approved for use in combination…Pre-treatment with Methanolic Extract Mucuna pruriens Seeds Attenuates Serotonin Gene Depletion, Motor Dysfunction and Anxiogenic Responses in a Rat Model of Parkinsonism
Objective: Investigate neuroprotective and genoprotective effects of methanolic Mucuna pruriens (Mp) seed extract in a paraquat-induced Parkinsonism rat model. Background: Paraquat exposure has been linked…Incobotulinumtoxin A to Treat Sialorrhea in Parkinson’s Disease: a Real-life Study: 5-year Interim Results
Objective: We evaluate the long-term efficacy and safety of incobotulinumtoxinA injections in advanced Parkinson’s disease (PD) patients suffering from sialorrhea (10 injection cycles (IC)). Background:…
- « Previous Page
- 1
- …
- 417
- 418
- 419
- 420
- 421
- …
- 1942
- Next Page »